Payment overview · 2025
General Payments
$929.10
34 reported records · 11 companies
Healthcare provider profile · identity verified
Charles Cho, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · LOS ANGELES, CA · NPI 1053512566
Verified facts
What the public records show
CMS Open Payments records show Charles Cho, M.D. received $929.10 in general payments during 2025 across 34 reported records.
Novartis Pharmaceuticals Corporation accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 699 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $270.14 | 29.1% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.20 | 12.7% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $117.08 | 12.6% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $80.59 | 8.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $69.53 | 7.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $67.46 | 7.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.13 | 5.6% | 2 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $46.82 | 5.0% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $46.78 | 5.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.31 | 5.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.06 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $929.10 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.20 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $117.08 | 4 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $80.59 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $69.53 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $67.46 | 3 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $46.78 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.31 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 138 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 699 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
138 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
699 | 142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
33 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2264 | 672 |
| Losartan Potassium | Losartan Potassium | 1159 | 334 |
| Metformin Hcl | Metformin Hcl | 894 | 255 |
| Jardiance | Empagliflozin | 699 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 630 | 182 |
| Tamsulosin Hcl | Tamsulosin Hcl | 552 | 169 |
| Omeprazole | Omeprazole | 527 | 195 |
| Vascepa | Icosapent Ethyl | 416 | 84 |
| Finasteride | Finasteride | 320 | 90 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 311 | 95 |
| Meloxicam | Meloxicam | 262 | 151 |
| Ozempic | Semaglutide | 258 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 57 |
| Allopurinol | Allopurinol | 220 | 65 |
| Glipizide | Glipizide | 209 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 59 |
| Januvia | Sitagliptin Phosphate | 202 | 40 |
| Alendronate Sodium | Alendronate Sodium | 191 | 60 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 186 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 168 | 52 |
| Prolia | Denosumab | 166 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 56 |
| Farxiga | Dapagliflozin Propanediol | 138 | 34 |
| Sildenafil Citrate | Sildenafil Citrate | 133 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 53 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 105 | 51 |
| Carvedilol | Carvedilol | 101 | 28 |
| Trulicity | Dulaglutide | 100 | 20 |
| Pregabalin | Pregabalin | 94 | 56 |
| Creon | Lipase/Protease/Amylase | 90 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 21 |
| Sevelamer Carbonate | Sevelamer Carbonate | 86 | 27 |
| Furosemide | Furosemide | 85 | 29 |
| Lisinopril | Lisinopril | 82 | 26 |
| Ciclopirox | Ciclopirox | 78 | 35 |
| Donepezil Hcl | Donepezil Hcl | 77 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 64 |
| Lidocaine | Lidocaine | 74 | 17 |
| Gabapentin | Gabapentin | 72 | 29 |
| Celecoxib | Celecoxib | 69 | 38 |
| Linzess | Linaclotide | 69 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 67 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 24 |
| Ketoconazole | Ketoconazole | 64 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 61 | 16 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 55 | 31 |
| Tadalafil | Tadalafil | 55 | 11 |
| Azithromycin | Azithromycin | 54 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 23 |
| Benazepril Hcl | Benazepril Hcl | 51 | 16 |
| Atenolol | Atenolol | 50 | 17 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 49 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 48 | 18 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 14 |
| Metformin Hcl Er | Metformin Hcl | 43 | 14 |
| Memantine Hcl | Memantine Hcl | 41 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 39 | 34 |
| Ursodiol | Ursodiol | 39 | 17 |
| Prednisone | Prednisone | 38 | 26 |
| Famotidine | Famotidine | 35 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 35 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | 12 |
| Simvastatin | Simvastatin | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 23 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | 12 |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 20 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 18 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 21 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Jublia | Efinaconazole | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $929.10 · 34 records | Novartis Pharmaceuticals Corporation | DAYBUE, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, JYNARQUE, REXULTI, TARPEYO, TRELEGY ELLIPTA, Vafseo, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error